Immunovant (IMVT) Free Cash Flow (2019 - 2026)

Immunovant (IMVT) has 8 years of Free Cash Flow data on file, last reported at -$95.0 million in Q1 2026.

• Quarterly Free Cash Flow rose 19.37% year-over-year to -$95.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$407.2 million (down 6.16% YoY) and the FY2026 annual result came in at -$407.2 million, down 6.16% from the prior year.
• Free Cash Flow retreated to -$95.0 million in Q1 2026, from -$92.3 million in the prior quarter.
• In the past five years, Free Cash Flow ranged from a high of -$20.2 million in Q3 2022 to a low of -$117.8 million in Q1 2025.
• A 5-year average of -$72.2 million and a median of -$65.9 million in 2022 frame the typical range for Free Cash Flow.
• Annual changes were most pronounced in 2022 — Free Cash Flow slumped 210.2% — and 2023, when it climbed 28.01%.
• Tracing IMVT's Free Cash Flow over 5 years: stood at -$46.5 million in 2022, then slipped by 1.3% to -$47.1 million in 2023, then plunged by 97.2% to -$92.9 million in 2024, then rose by 0.6% to -$92.3 million in 2025, then fell by 2.89% to -$95.0 million in 2026.
• The last three Free Cash Flow figures came in at -$95.0 million (Q1 2026), -$92.3 million (Q4 2025), and -$102.5 million (Q3 2025), per Business Quant data.